Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01646593|
Expanded Access Status : No longer available
First Posted : July 20, 2012
Last Update Posted : December 15, 2014
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.
|Condition or disease||Intervention/treatment|
|Gastrointestinal Stromal Tumors||Drug: Regorafenib (BAY73-4506)|
|Study Type :||Expanded Access|
|Official Title:||An Open-label Expanded Access Program of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib|
- Drug: Regorafenib (BAY73-4506)
160 mg BAY73-4506, 3 weeks on drug, 1 week off
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01646593
|Study Director:||Bayer Study Director||Bayer|